OIVD Issues Warning Letter For Cancer Screening Software
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of In Vitro Diagnostic Device Evaluation & Safety cited BioImagene in a May 25 FDL-1warning letter for marketing its software tool Pathiam as a diagnostic device without 510(k) clearance or marketing approval